Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.

about

Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.

Item

http://www.wikidata.org/entity/Q48287544

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Brentuximab vedotin in patient ...... d Kingdom retrospective study.

@en

Brentuximab vedotin in patient ...... d Kingdom retrospective study.

@nl

type

Item

label

Brentuximab vedotin in patient ...... d Kingdom retrospective study.

@en

Brentuximab vedotin in patient ...... d Kingdom retrospective study.

@nl

prefLabel

Brentuximab vedotin in patient ...... d Kingdom retrospective study.

@en

Brentuximab vedotin in patient ...... d Kingdom retrospective study.

@nl

P1476

Brentuximab vedotin in patient ...... d Kingdom retrospective study.

@en

P2093

Brian Seal

http://www.w3.org/2001/XMLSchema#string

Courtney Johnson

http://www.w3.org/2001/XMLSchema#string

Cynthia Macahilig

http://www.w3.org/2001/XMLSchema#string

Erin A Zagadailov

http://www.w3.org/2001/XMLSchema#string

Mehul R Dalal

http://www.w3.org/2001/XMLSchema#string

Paul J Bröckelmann

http://www.w3.org/2001/XMLSchema#string

Viktor Chirikov

http://www.w3.org/2001/XMLSchema#string

P2860

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.

Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

P304

553-558

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/EJH.12973

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tim M. Illidge

Shelby Corman

P577

2017-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28949403

http://www.w3.org/2001/XMLSchema#string

P921

A' Ghearmailt